Advanced Prostate Cancer Immunotherapy in Germany

Immunogenic Cell Death (ICD) refers to a specific, immunologically active form of tumor cell death one that does not simply eliminate cells quietly, but does so in a way that raises an immune alarm.

Not all forms of cell death are immunogenic. Standard chemotherapy and radiation can cause tumor cell death that is largely non-immunogenic the cells die silently, without triggering a meaningful immune response.

This is why a deliberate ICD-inducing pre-treatment step is considered essential before dendritic cell vaccination.

Why ICD is necessary before Dendritic Cell Therapy for Prostate Cancer:

• ICD-inducing agents (such as specific chemotherapeutic protocols, hypericin-based photodynamic therapy, or oncolytic viruses like NDV) create a rich source of tumor antigens released in an immunologically active context essential raw material for loading DCs.

• The DAMPs released during ICD directly activate DCS in the tumor microenvironment and in the bloodstream, making them more responsive to subsequent vaccination.

• ICD partially reverses the immune-suppressive tumor microenvironment, allowing T cells and DCs to function where previously they were silenced.

• Without a preceding ICD step, Dcs loaded with tumor antigens may fail to generate a sufficiently strong T cell response the immune system has not been adequately primed to recognize the tumor as a threat.

• ICD converts the tumor into an in-situ vaccine, ensuring that the antigens presented to DCs are authentic, patient-specific, and presented in a pro-inflammatory context.

In clinical protocols combining NDV with dendritic cell vaccine for prostate cancer, the virus serves the dual role of oncolytic agent and ICD inducer killing tumor cells immunogenically and thereby preparing the immune landscape for the dendritic cell vaccine for prostate cancer that follows.

One of the greatest challenges in cancer treatment is making the immune system recognize cancer cells as dangerous. This is where Immunogenic Cell Death (ICD) therapy has attracted significant scientific interest.

ICD therapy aims to kill cancer cells in a way that sends strong danger signals to the immune system. Instead of dying silently, cancer cells release molecules that act like alarm bells. These signals attract dendritic cells and other immune cells to the tumor environment.

Furthermore, Newcastle Disease Virus (NDV) has been studied as an oncolytic virus because it preferentially infects and damages cancer cells while stimulating immune activity. When tumor cells are infected by NDV, they can release a broad range of tumor antigens and danger-associated molecular patterns. This process may help transform an immunologically “cold” tumor into a more immunologically “hot” tumor.

As a result, dendritic cells receive significantly more information about the cancer. They can then present these tumor antigens to T-cells more efficiently, potentially leading to a stronger immune response.

Another important concept is the abscopal effect. This phenomenon occurs when local treatment of one tumor site leads to immune-mediated responses in distant tumor sites elsewhere in the body. Researchers believe that strong systemic immune activation is necessary for this effect to occur.

Consequently, a dendritic cell vaccine administered without sufficient tumor antigen release may not provide the same level of immune stimulation. By contrast, combining ICD therapy with NDV and dendritic cell vaccination may create a more comprehensive immune response because the immune system receives both the “target information” and the “activation signals” required for effective anti-cancer activity.

For this reason, many integrative immunotherapy approaches focus on combining dendritic cell vaccination with therapies that promote immunogenic cell death rather than relying on a vaccine alone.